Christopher Yea - Nov 1, 2021 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: Chief Development Officer
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol: KALV
Transactions as of: Nov 1, 2021
Transactions value $: -$90,328
Form type: 4
Date filed: 11/3/2021, 04:56 PM
Previous filing: Aug 4, 2021
Next filing: May 19, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALV	Common Stock	Sale	-$90.3K	-5K	-13.17%	$18.07	33K	Nov 1, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69 to $18.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Content

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69 to $18.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.